Bimatoprost: A member of a new class of agents, the prostamides, for glaucoma management

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Bimatoprost, a synthetic analogue of endogenous prostamides, is in development as a topical ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. Prostamides are a newly discovered class of compounds that have been shown to have potent ocular hypotensive activity in the laboratory. Bimatoprost mimics the endogenous prostamides by lowering intraocular pressure (IOP). Bimatoprost provides outstanding control of IOP throughout the day, and a high percentage of patients receiving bimatoprost achieve the low target pressures important for clinical success. In controlled clinical trials, bimatoprost 0.03% given once daily has displayed efficacy superior to timolol 0.5% given twice daily, the current standard for therapy. Analysis of pooled six month data from two large Phase III trials demonstrated that mean IOP was consistently 2 - 3 mmHg lower with bimatoprost q.d. than with timolol b.i.d. Bimatoprost 0.03% q.d. has also been shown to provide significantly better diurnal IOP control than latanoprost 0.005% q.d., probably the most efficacious topical medication currently available. Patients receiving bimatoprost q.d. were more likely than timolol or latanoprost patients to achieve low target pressures. In all clinical evaluations, bimatoprost q.d. has been demonstrated to be safe and well-tolerated. Bimatoprost will likely be available for clinical use in 2001 and it has great potential to be superior to all other medications in IOP-lowering efficacy. It is anticipated that bimatoprost will have an important role in therapy for glaucoma and ocular hypertension.

Original languageEnglish (US)
Pages (from-to)721-731
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume10
Issue number4
DOIs
StatePublished - Apr 23 2001

Fingerprint

Glaucoma
Intraocular Pressure
latanoprost
Timolol
Ocular Hypertension
Bimatoprost
Pressure
Controlled Clinical Trials
Therapeutics

Keywords

  • AGN 192024
  • Bimatoprost
  • Glaucoma
  • Intraocular pressure
  • Latanoprost
  • Ocular hypertension
  • Prostamide
  • Timolol

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bimatoprost : A member of a new class of agents, the prostamides, for glaucoma management. / Cantor, L. B.

In: Expert Opinion on Investigational Drugs, Vol. 10, No. 4, 23.04.2001, p. 721-731.

Research output: Contribution to journalArticle

@article{42e9dea7d8064c5aad4547ca9bf2cb74,
title = "Bimatoprost: A member of a new class of agents, the prostamides, for glaucoma management",
abstract = "Bimatoprost, a synthetic analogue of endogenous prostamides, is in development as a topical ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. Prostamides are a newly discovered class of compounds that have been shown to have potent ocular hypotensive activity in the laboratory. Bimatoprost mimics the endogenous prostamides by lowering intraocular pressure (IOP). Bimatoprost provides outstanding control of IOP throughout the day, and a high percentage of patients receiving bimatoprost achieve the low target pressures important for clinical success. In controlled clinical trials, bimatoprost 0.03{\%} given once daily has displayed efficacy superior to timolol 0.5{\%} given twice daily, the current standard for therapy. Analysis of pooled six month data from two large Phase III trials demonstrated that mean IOP was consistently 2 - 3 mmHg lower with bimatoprost q.d. than with timolol b.i.d. Bimatoprost 0.03{\%} q.d. has also been shown to provide significantly better diurnal IOP control than latanoprost 0.005{\%} q.d., probably the most efficacious topical medication currently available. Patients receiving bimatoprost q.d. were more likely than timolol or latanoprost patients to achieve low target pressures. In all clinical evaluations, bimatoprost q.d. has been demonstrated to be safe and well-tolerated. Bimatoprost will likely be available for clinical use in 2001 and it has great potential to be superior to all other medications in IOP-lowering efficacy. It is anticipated that bimatoprost will have an important role in therapy for glaucoma and ocular hypertension.",
keywords = "AGN 192024, Bimatoprost, Glaucoma, Intraocular pressure, Latanoprost, Ocular hypertension, Prostamide, Timolol",
author = "Cantor, {L. B.}",
year = "2001",
month = "4",
day = "23",
doi = "10.1517/13543784.10.4.721",
language = "English (US)",
volume = "10",
pages = "721--731",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
number = "4",

}

TY - JOUR

T1 - Bimatoprost

T2 - A member of a new class of agents, the prostamides, for glaucoma management

AU - Cantor, L. B.

PY - 2001/4/23

Y1 - 2001/4/23

N2 - Bimatoprost, a synthetic analogue of endogenous prostamides, is in development as a topical ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. Prostamides are a newly discovered class of compounds that have been shown to have potent ocular hypotensive activity in the laboratory. Bimatoprost mimics the endogenous prostamides by lowering intraocular pressure (IOP). Bimatoprost provides outstanding control of IOP throughout the day, and a high percentage of patients receiving bimatoprost achieve the low target pressures important for clinical success. In controlled clinical trials, bimatoprost 0.03% given once daily has displayed efficacy superior to timolol 0.5% given twice daily, the current standard for therapy. Analysis of pooled six month data from two large Phase III trials demonstrated that mean IOP was consistently 2 - 3 mmHg lower with bimatoprost q.d. than with timolol b.i.d. Bimatoprost 0.03% q.d. has also been shown to provide significantly better diurnal IOP control than latanoprost 0.005% q.d., probably the most efficacious topical medication currently available. Patients receiving bimatoprost q.d. were more likely than timolol or latanoprost patients to achieve low target pressures. In all clinical evaluations, bimatoprost q.d. has been demonstrated to be safe and well-tolerated. Bimatoprost will likely be available for clinical use in 2001 and it has great potential to be superior to all other medications in IOP-lowering efficacy. It is anticipated that bimatoprost will have an important role in therapy for glaucoma and ocular hypertension.

AB - Bimatoprost, a synthetic analogue of endogenous prostamides, is in development as a topical ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. Prostamides are a newly discovered class of compounds that have been shown to have potent ocular hypotensive activity in the laboratory. Bimatoprost mimics the endogenous prostamides by lowering intraocular pressure (IOP). Bimatoprost provides outstanding control of IOP throughout the day, and a high percentage of patients receiving bimatoprost achieve the low target pressures important for clinical success. In controlled clinical trials, bimatoprost 0.03% given once daily has displayed efficacy superior to timolol 0.5% given twice daily, the current standard for therapy. Analysis of pooled six month data from two large Phase III trials demonstrated that mean IOP was consistently 2 - 3 mmHg lower with bimatoprost q.d. than with timolol b.i.d. Bimatoprost 0.03% q.d. has also been shown to provide significantly better diurnal IOP control than latanoprost 0.005% q.d., probably the most efficacious topical medication currently available. Patients receiving bimatoprost q.d. were more likely than timolol or latanoprost patients to achieve low target pressures. In all clinical evaluations, bimatoprost q.d. has been demonstrated to be safe and well-tolerated. Bimatoprost will likely be available for clinical use in 2001 and it has great potential to be superior to all other medications in IOP-lowering efficacy. It is anticipated that bimatoprost will have an important role in therapy for glaucoma and ocular hypertension.

KW - AGN 192024

KW - Bimatoprost

KW - Glaucoma

KW - Intraocular pressure

KW - Latanoprost

KW - Ocular hypertension

KW - Prostamide

KW - Timolol

UR - http://www.scopus.com/inward/record.url?scp=0035066590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035066590&partnerID=8YFLogxK

U2 - 10.1517/13543784.10.4.721

DO - 10.1517/13543784.10.4.721

M3 - Article

C2 - 11281821

AN - SCOPUS:0035066590

VL - 10

SP - 721

EP - 731

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 4

ER -